Biotome Pty Ltd
Biotome, founded in 2017 by Professor Samuel Lundin, Dr Alma Fulurija and Nobel Laureate Professor Barry Marshall, is developing next-generation serology tests (antibody-tests) based on precision immunology.
The COVID-19 pandemic has exposed the large performance issues of current antibody-test technologies. Our antibody tests are more informative and provide higher accuracy than current technology and will provide value in a range of disease diagnosis markets, including stomach cancer and SARS-CoV-2 infection.
The choice you make above will help our platform display content that is best suited to you
Welcome to the new Wholesale Investor platform. Please use your existing log in details to access the site. Alternatively feel free to use the "Login with LinkedIn" or "Sign in with Google" buttons.
Enter your email to reset your password.